**European Committee on Antimicrobial Susceptibility Testing**

**Seventh EUCAST steering committee meeting**

**Summary of minutes of meeting in Prague, Czech Republic, 30 April 2004**

### Attending

<table>
<thead>
<tr>
<th>Attending</th>
<th>Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Derek F.J. Brown</td>
<td>DB</td>
<td>Scientific Secretary</td>
</tr>
<tr>
<td>Dr Fred Goldstein</td>
<td>FG</td>
<td>SFM</td>
</tr>
<tr>
<td>Dr Gunnar Kahlmeter</td>
<td>GK</td>
<td>Chairperson</td>
</tr>
<tr>
<td>Prof Alasdair P. MacGowan</td>
<td>AM</td>
<td>BSAC</td>
</tr>
<tr>
<td>Dr Johan W. Mouton</td>
<td>JM</td>
<td>CRG</td>
</tr>
<tr>
<td>Dr Ingrid Nilsson-Ehle</td>
<td>IN-E</td>
<td>SRGA</td>
</tr>
<tr>
<td>Dr Martin Steinbakk</td>
<td>MS</td>
<td>NWGA</td>
</tr>
<tr>
<td>Dr Pavla Urbaskova</td>
<td>PU</td>
<td>EUCAST</td>
</tr>
<tr>
<td>Dr Alkiviadis Vatopoulos</td>
<td>AV</td>
<td>EUCAST</td>
</tr>
</tbody>
</table>

### Apologies

<table>
<thead>
<tr>
<th>Apologies</th>
<th>Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Anders Österlund</td>
<td>AO</td>
<td>SRGA</td>
</tr>
<tr>
<td>Dr Arne Rodloff</td>
<td>AR</td>
<td>DIN</td>
</tr>
</tbody>
</table>

1. **Chairman’s welcome and report**
   - Minutes of meeting of 3 February 2004 accepted as a correct record.

2. **Minutes of meeting of 3 February 2004**
   - Minutes of meeting of 3 February 2004 accepted as a correct record.
   - Declarations of interest were noted. The current form would be reviewed next year. Information on interests must be requested in writing and will be given in writing.
   - Comments on proposed breakpoints and Steering Committee responses to be updated.
   - Instructions for access to EUCAST websites have been redistributed and a bug fixed.
   - All expense claims be sent via GK for Chairman's approval.
   - Draft procedure for setting breakpoints is on the EUCAST public website for comment.
   - Response sent to letter from Bayer.

3. **Matters arising from minutes of 3 February 2004**
   - Aminoglycoside breakpoints. No comments on proposed breakpoints had been received.
   - Breakpoints finalised.

4. **Linezolid breakpoints**
   - No comments on proposed breakpoints had been received.
   - Breakpoints finalised.

5. **Glycopeptide breakpoints**
   - Comments received from Aventis were discussed.
   - Agreed to include a footnote on referring to national methods for recommendations.
   - Breakpoints finalised.

6. **Quinolone breakpoints**
   - Agreed that when assessing any breakpoints, the pharmacokinetic data provided by companies should be interpreted as appropriate by the Steering Committee and this interpretation may be different from that provided by the company.
   - The pharmacodynamic data in relation to moxifloxacin and levofloxacin in relation to pneumococci were discussed and breakpoints agreed.
   - Agreed footnote 1 to the quinolone table should indicate that the data on *Salmonella* and ciprofloxacin relate mainly to *S typhi*. 
Breakpoints finalised.

<table>
<thead>
<tr>
<th>8</th>
<th>Carbapenem breakpoints. Background data were reviewed - additional data are needed.</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Cephalosporin breakpoints Some MIC data have been received. There were preliminary discussions on breakpoints.</td>
</tr>
<tr>
<td>10</td>
<td>Agreed that a table template for comments on any breakpoints, with space for the Steering Committee response, would be posted on the website.</td>
</tr>
</tbody>
</table>

Rationale documents
The format was discussed. All would be involved in adding to rationale documents.
Agreed that European SPCs would be source of pk/pd data unless not available or unacceptable.

EUCAST Committee membership
General Committee members have been asked to confirm membership of the General Committee.
Applications to be General Committee representatives on the Steering Committee were received on behalf of Olga Stetsiouk (Russia) and Francisco Soriano (Spain) and these had been approved at the ESCMID Board meeting on 29 April 2004.
As this was their last meeting, PU and AV were thanked for their contributions and good humour.

CEN/ISO
Reported that the joint meeting of CEN and ISO committees on 22 April 2004 had been very positive and good progress had been made towards a reference broth microdilution method.

EMEA
An EMEA Standard Operating Procedure is being prepared with involvement of EUCAST in setting breakpoints for new agents by both the centralised and mutual recognition pathways.
Noted that EMEA had no jurisdiction over old breakpoints, but harmonised EUCAST breakpoints will be considered at 5-year re-evaluations.

ECCMID meeting Prague
The EUCAST General Committee meeting and symposium would both be held on 3 May 2004.

Finance
The DG-SANCO grant would run from 1 May 2004 to 30 April 2007.

EUCAST documents
Nothing new to report.

EARSS
EARSS Advisory Board and Country Representative meetings had been held recently.
An application has been made by a consortium of UKNEQAS, EUCAST, EARSS and the Polish Centre for QC to DG-SANCO for funds for an EQA scheme for national reference laboratories.

Any other business
Daptomycin breakpoints would be considered at the September 2004 meeting.
Tigecycline breakpoints might also be considered this year.
Will need to consider relationships with networks which have set their own breakpoints (eg Neisseria gonorrhoeae, Neisseria meningitidis), with the EMA and with the new European Centre for Disease Prevention and Control.

Next meetings
6-7 September 2004 Munich.
22-23 November, venue to be decided.
Early February 2005 if required.
31 March-1 April 2005, Prior to ECCMID 2005, Copenhagen

Ratified minutes summary 7 September 2004
Prepared by DB and GK